PMA device
Hymovis One
Fidia Farmaceutici · Acid, Hyaluronic, Intraarticular (MOZ, Class III) · First FDA decision Apr 9, 2025, newest Apr 9, 2025Knee osteoarthritis
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
PMA pathway
Device trials
3
Naming "Hymovis One"
MAUDE reports
0
Brand "Hymovis One", since 2015
PubMed studies
3
Mentioning "Hymovis One"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Hymovis One
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- HYMOVIS ONEPMA supplement
P150010-S005 · Decided Apr 9, 2025 · 107 days after receipt · Panel Track
Device type: Acid, hyaluronic, intraarticular (MOZ) · Orthopedic Surgery
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Hymovis One", any status and sponsor, newest update first.
- Comparative Study of Two Hyaluronic Acid Formulation in the Management of Knee OsteoarthritisPivotal-lookingCompleted
Fidia Farmaceutici s.p.a.Not on our public-company list
NCT06528600 · 350 participants · Start Sep 16, 2020 · Primary completion Mar 15, 2024
Device: Hymovis ONE; Monovisc · For: Osteoarthritis, Knee
Sites: Brescia, Italy; Esine, Italy; Caserta, Italy · 19 sites in all
Fidia Farmaceutici s.p.a.Not on our public-company list
NCT04661111 · 31 participants · Start Jun 13, 2016 · Primary completion Sep 28, 2017
Device: Hymovis® ONE (32 mg/4 ml) · For: Knee Osteoarthritis
Sites: Roma, Italy
Fidia Farmaceutici s.p.a.Not on our public-company list
NCT04293861 · 50 participants · Start Apr 1, 2015 · Primary completion Jun 6, 2017
Device: HYMOVIS · For: Knee Osteoarthritis
Sites: Yvoir, Belgium; Brussels, Belgium; Liège, Belgium · 8 sites in all
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Hymovis One", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code MOZ
4,975 reports: 669 malfunction, 3,945 injury, 278 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Hymovis One"[tiab]. The summary above synthesizes these.
- Single-injection hyaluronic acid treatment demonstrates non-inferiority in the relief of symptomatic knee osteoarthritis: A randomized double-blind, multi-center controlled study.
Ruosi C, Longo UG, Giordan N, et al. · Osteoarthr Cartil Open · 2026
- Efficacy of a Single Intra-Articular HYMOVIS ONE Injection for Managing Symptomatic Hip Osteoarthritis: A 12-Month Follow-Up Retrospective Analysis of the ANTIAGE Register Data.
Migliore A, Frediani B, Gigliucci G, et al. · Orthop Res Rev · 2020
- Rheological properties and clinical efficacy of a chemically modified hyaluronic acid for joint health enhancement.
Benazzo F, Bernetti A · Drugs Context · 2026Review
Other devices of this type
Also filed under product code MOZ.
- EUFLEXXA (1% Sodium Hyaluronate)Ferring Pharmaceuticals, Inc. · PMA 2017
- Gel-One(R)Seikagaku Corp. · PMA 2016
- Supartz FxSeikagaku Corp. · PMA 2016
- SupartzSeikagaku Corp. · PMA 2015
- Orthovisc High Molecular Weight HyaluronanAnika Therapeutics, Inc. · PMA 2011
- DurolaneBioventus, LLC · PMA 2020
- MonoviscAnika Therapeutics, Inc. · PMA 2020
- HyalganFidia Farmaceutici S.P.A. · PMA 2008
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.